Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration, Oncology, and Cardiovascular Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Sortilin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Sortilin ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Sortilin Products |
| Gene Delivery | Sortilin Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native conformation for internalization assays. |
View Sortilin Products |
| Benchmark Ab | Anti-Sortilin (Neutralizing Clone) Recombinant positive control for binding competition. |
View Sortilin Products |
| Validator | Sortilin siRNA Set For knockdown verification and specificity controls. |
View Sortilin Products |
| Ligand Control (PCSK9) | PCSK9 Protein Primary ligand for SORT1 binding assays. Sequence Verified. |
View PCSK9 Products |
| Ligand Control (PGRN) | Progranulin (PGRN) Protein Critical ligand for neurodegeneration therapeutic blocking. Sequence Verified. |
View PGRN Products |
| Selectivity Panel | SORCS2 ECD-Fc VPS10P family member for off-target screening. |
View SORCS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Lysosomal Trafficking Internalization (ADC Development) | Full-length Lentivirus for stable cell lines. Endotoxin controlled (<1EU/ug) for sensitive neuronal assays. |
| VPS10P Family Selectivity (SORCS1/2/3, CIMPR) | Ortholog panel proteins strictly verified by mass spec. Human/Mouse/Cyno available. |
| pH-Dependent Ligand Release (Endosomal pH 5.5) | ECD-Fc engineered for conformational stability across pH 4.0-7.4. High-purity (>95%) for SPR/Biacore. |
| Cross-species Preclinical Evaluation | Human/Cyno/Mouse Sortilin proteins with sequence identity verification. |
| Lack of Positive Controls | Clinical Benchmark Antibodies included for direct affinity and functional comparison. |
| False Positive Screening | Validated siRNA included for specificity checks in cell-based screening. |
Live Sortilin (SORT1) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Sortilin therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and targeted peptide-drug conjugates leveraging SORT1's rapid internalization and lysosomal delivery properties. As first-generation cardiovascular programs (targeting PCSK9 co-regulation) reach maturity, the next wave of R&D is targeting neurodegenerative disorders through progranulin pathway modulation and solid tumor indications (e.g., breast, ovarian, and melanoma) via ADC payloads.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Roche, Theratechnologies, Emerging Biotech | Solid Tumors (Ovarian, Breast, SORT1+) | Internalization Assay (Need high-purity ECD-Fc for binding, Lentivirus for trafficking) |
| Blocking mAb | Neuroscience Biotechs | Alzheimer's, FTD | Progranulin Competition Assay (Need PCSK9 & GRN ligand controls) |
| Bispecific | Immunotherapy Focused | GBM, Pancreatic | Heterodimer Validation (Need Cross-reactive Abs, Selectivity vs SORCS family) |
| Small Molecule | Cardiovascular Division | Hypercholesterolemia | Binding Site Displacement (Need mutant vs WT proteins) |